Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs
Key facts
- Where
- San Francisco, United StatesSee the site
Where in United States
- Quaker Meeting HouseSan Francisco, United StatesContact: Morris Meghan, PhDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of California, San Francisco
- Trial code
- NCT07631559
- Record updated
- 8 June 2026
- Original description
This study builds upon an ongoing NIH-funded randomized controlled trial (R01DA053325) evaluating a Partner Navigation Intervention to increase hepatitis C virus (HCV) treatment initiation among young adult people who inject drugs (PWID) and their injecting partners in San Francisco. The proposed research includes secondary analyses of existing trial data, additional survey measures, qualitative interviews, and a pilot intervention adaptation.Read full original descriptionShow less
This study builds upon an ongoing NIH-funded randomized controlled trial (R01DA053325) evaluating a Partner Navigation Intervention to increase hepatitis C virus (HCV) treatment initiation among young adult people who inject drugs (PWID) and their injecting partners in San Francisco. The proposed research includes secondary analyses of existing trial data, additional survey measures, qualitative interviews, and a pilot intervention adaptation.
The study has two primary objectives. First, it examines how racialized discrimination (structural, interpersonal, and internalized) affects HCV treatment initiation and dyadic partner support processes within injecting partnerships. Second, it evaluates whether a brief, adapted "booster" partner navigation session delivered at HCV treatment completion can improve engagement in ongoing healthcare.
Participants include adults (≥18 years) who inject drugs and have been diagnosed with HCV, along with their primary injecting partners. Study activities include longitudinal surveys, qualitative interviews with a subset of participants, and a pilot intervention session with follow-up evaluation.
This research addresses critical gaps in understanding how social relationships and structural inequities influence healthcare engagement among PWID. Findings will inform culturally responsive adaptations to dyadic interventions and improve continuity of care in a population disproportionately affected by HCV and systemic barriers to healthcare.
Inclusion: For index participants:; 18 years of age or older at enrollment; History of injecting drug use; Completed HCV treatment within the past 3 months; Report a primary injecting partner willing to participate; Willing and able to provide informed consent; English or Spanish speaking; For primary injecting partners:; Primary injecting partner of an enrolled index participant:; 18 years of age or older at enrollment; Willing and able to provide informed consent; English or Spanish speaking; has context menu.
Exclusion: Previously participated in this study in any capacity; Unable to provide informed consent due to cognitive impairment or acute intoxication at the time of enrollment; For both index participants and injecting partners:.